A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
Public ClinicalTrials.gov record NCT03142191. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment doses of CC-90001, 200 mg and 400 mg, compared with placebo, when delivered once daily per os (PO) in subjects with idiopathic pulmonary fibrosis (IPF). This study is designed to assess response to treatment by using measures of lung function, disease progression, fibrosis on radiography, and patient-reported outcomes. It will also assess dose response.
Study identification
- NCT ID
- NCT03142191
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 26, 2017 (Actual)
- Primary completion
- Dec 24, 2021 (Actual)
- Completion
- Dec 24, 2021 (Actual)
- Last update posted
- Jun 28, 2023
2017 – 2021
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Loma Linda Univ Medical Center | Loma Linda | California | 92354 | — |
| Cedars Sinai Medical Center Rheumatology | Los Angeles | California | 90048 | — |
| Local Institution - 514 | Sacramento | California | 95817 | — |
| University of California Davis Health System | Sacramento | California | 95817 | — |
| Stanford University Pulmonary and Critical Care Clinic | Stanford | California | 94305 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| University of Miami and Sylvester Cancer Center | Miami | Florida | 33136 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| The Lung and Research Center, LLC | Chesterfield | Missouri | 63017 | — |
| Mt. Sinai School of Medicine | New York | New York | 10029 | — |
| Duke University Health System - Duke Pulmonary Transplant Clinic | Durham | North Carolina | 27710 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45267 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44121 | — |
| Pulmonary & Sleep Center of Oklahoma | Tulsa | Oklahoma | 74137 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37212 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Local Institution - 502 | Dallas | Texas | 75246 | — |
| University of Utah Health Care | Salt Lake City | Utah | 84132 | — |
| University of Vermont | Burlington | Vermont | 05405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03142191, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 28, 2023 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03142191 live on ClinicalTrials.gov.